Yaël P Mossé

16PUBLICATIONS
148CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyPredictive and prognostic markersComputational neuroscience (incl. mathematical neuroscience and theoretical neuroscience)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

|Apr 06, 2026
Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.

Edward Favours, Haiying Tang, Peyton Wong

|Aug 14, 2025
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers.

Alberto D Guerra, Smita Matkar, Christina Acholla

|Aug 06, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity.

John Maris, Isabel Soria-Bretones, Matias Casás-Selves

|Jun 23, 2025
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Thomas Cash, Araz Marachelian, Steven G DuBois

|Mar 04, 2025
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.

Esther R Berko, Arlene Naranjo, Alexander A Daniels

Pageof 3

Frequent Collaborators

13 joint publications

John Maris

5 joint publications

David Groff

4 joint publications

Colleen E Casey

4 joint publications

Mark Gerelus